The Federal Office relies on reports from consumers, health care professionals and companies for the continuous re-evaluation of the safety profile of medicinal products and medical devices.
The transition period ended on 31.12.2020. Marketing authorisation holders are reminded to submit any outstanding amendments without delay.
The BASG authorises and monitors the conduct of clinical trials with medicinal products and medical devices.
The Austrian Pharmacopoeia (ÖAB) is a national addendum to the European Pharmacopoeia and is currently being revised by the ÖAB Commission.